Cell Signaling: How Cells ‘Talk’ to Each Other

The Problem of Coordination in Multicellular Life

A human body contains approximately 37 trillion cells, each enclosed within its own lipid bilayer membrane and operating a semi-autonomous biochemical programme. Yet despite this physical separation, tissues contract in unison, immune cells converge on sites of infection within minutes, and developing organs know precisely when to stop growing. This coordination is not accidental. It depends on an elaborate molecular communication infrastructure that biologists call cell signaling: the mechanisms by which cells produce, transmit, receive, and respond to chemical information.

Cell signaling is not a peripheral feature of multicellular life; it is its defining requirement. Without the capacity to exchange signals, collections of cells would remain mere aggregates, incapable of forming organised tissues or executing the division of physiological labour that makes complex organisms possible. Even single-celled organisms rely on chemical signaling to sense environmental conditions and coordinate behaviour within populations, as demonstrated by quorum sensing in bacteria. The study of cell signaling therefore sits at the intersection of virtually every domain of modern biology, from developmental genetics to pharmacology.

Understanding how cells talk to each other requires examining four fundamental questions: what molecules carry the message, how far those molecules travel, what molecular machinery receives them, and what happens inside the receiving cell as a consequence. Each of these questions opens into extraordinary mechanistic depth, and together they define one of the most productive areas of biological research in the last half-century.

The Chemical Language: Signaling Molecules and Their Range

The molecules that carry signals between cells are collectively called ligands, a term that emphasises their functional relationship with the receptor proteins they bind. Ligands are extraordinarily chemically diverse. They include small hydrophilic molecules such as amino acid derivatives and peptides, large glycoprotein hormones, lipid-soluble steroids, dissolved gases such as nitric oxide, and even ions. This chemical diversity is not arbitrary; it encodes information about how far a signal can travel, how quickly it can act, and what kinds of cells it can reach.

Biologists classify intercellular signaling according to the distance over which it operates. Endocrine signaling is the longest-range modality: specialised glands secrete hormones directly into the bloodstream, which carries them throughout the organism. Insulin, secreted by pancreatic beta cells, and cortisol, released from the adrenal cortex, are canonical examples. Because endocrine signals must survive circulation and reach targets throughout the body, they are typically stable molecules present at nanomolar to picomolar concentrations in blood plasma. The specificity of their action is not determined by where they travel but by which cells express the appropriate receptor.

Paracrine signaling operates over shorter distances, typically spanning only a few cell diameters. Signaling molecules secreted by one cell diffuse through the extracellular space and act on neighbouring cells. Growth factors released during tissue repair exemplify this mode, as do the morphogens that establish positional information gradients in developing embryos. Juxtacrine signaling is even more spatially restricted, requiring direct physical contact between cells: a membrane-bound ligand on one cell binds a receptor on an immediately adjacent cell, as occurs with Notch-Delta signaling during cell fate determination in neural development.

Autocrine signaling represents a special case in which a cell secretes a ligand that acts on receptors it itself expresses. This mode is particularly important in immune activation and in cancer biology, where autocrine loops can drive sustained, ligand-independent proliferative signalling. Synaptic signaling, the fastest and most spatially precise form, occurs at the chemical synapse: a presynaptic neuron releases neurotransmitters into the narrow synaptic cleft, typically 20 to 40 nanometers (nm) wide, and these molecules diffuse to postsynaptic receptors within milliseconds. The physical confinement of the synapse ensures signal speed and specificity simultaneously.

Receptors: The Molecular Listeners

A ligand carries no information unless there is a receptor capable of receiving it. Receptors are proteins, usually transmembrane proteins, that bind specific ligands with high affinity and selectivity and convert that binding event into a change in cellular biochemistry. The specificity of a receptor for its ligand is determined by the three-dimensional architecture of the binding site, which is shaped by the receptor’s amino acid sequence and post-translational modifications. A cell’s signaling identity, what signals it can detect and respond to, is therefore defined by its receptor repertoire.

G Protein-Coupled Receptors

G protein-coupled receptors (GPCRs) constitute the largest family of cell surface receptors in the human genome, with approximately 800 members identified in humans. Their canonical structure consists of seven transmembrane alpha-helical segments that weave back and forth through the plasma membrane, creating an extracellular ligand-binding domain and an intracellular surface that couples to heterotrimeric G proteins. Ligand binding induces a conformational change in the receptor that causes it to act as a guanine nucleotide exchange factor (GEF), catalysing the exchange of GDP for GTP on the alpha subunit of the associated G protein. The GTP-bound alpha subunit dissociates from the beta-gamma dimer, and both components diffuse within the membrane to modulate downstream effectors such as adenylyl cyclase, phospholipase C, or ion channels.

The diversity of GPCR signaling arises from the combinatorial variety of G protein subtypes: Gs stimulates adenylyl cyclase to produce cyclic AMP (cAMP), Gi inhibits it, Gq activates phospholipase C to generate inositol trisphosphate (IP3) and diacylglycerol (DAG), and G12/13 couples to Rho GTPase pathways. Signal termination is achieved when the intrinsic GTPase activity of the alpha subunit hydrolyses GTP back to GDP, restoring the inactive heterotrimer. Receptor desensitisation involves phosphorylation of the activated receptor by G protein-coupled receptor kinases (GRKs), followed by beta-arrestin binding, which sterically prevents further G protein coupling and targets the receptor for endocytosis.

Receptor Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are a family of approximately 58 human receptor proteins that couple ligand binding directly to intracellular enzymatic activity. They share a common architecture: a single transmembrane helix connects an extracellular ligand-binding domain to an intracellular segment containing a catalytic tyrosine kinase domain. In the absence of ligand, most RTKs exist as monomers with low or negligible kinase activity. Ligand binding, typically by dimeric or bivalent growth factors such as epidermal growth factor (EGF) or platelet-derived growth factor (PDGF), induces receptor dimerisation. Within the dimer, the two kinase domains transphosphorylate each other on specific tyrosine residues in the activation loop, relieving autoinhibition and generating full catalytic activity.

The phosphorylated tyrosine residues on the intracellular tail then serve as docking sites for proteins containing Src homology 2 (SH2) domains or phosphotyrosine-binding (PTB) domains. These adaptor and effector proteins are recruited in a phosphotyrosine-dependent manner and assemble into signaling complexes that activate downstream cascades. The Ras/MAPK pathway, the PI3K/Akt pathway, and the STAT pathway are the three primary effector arms downstream of RTK activation, and their relative engagement is determined by the specific phosphorylation pattern on each RTK and the complement of SH2-domain proteins expressed in a given cell type.

Ion Channel Receptors and Nuclear Receptors

Ligand-gated ion channels represent a third major receptor class in which the receptor and the effector are a single molecular entity. Binding of a neurotransmitter such as acetylcholine to the nicotinic acetylcholine receptor opens an intrinsic cation-selective pore within milliseconds, producing an immediate change in membrane potential. This direct coupling of ligand binding to ion flux makes ligand-gated channels the fastest signal transducers at chemical synapses, with response times measured in tens of milliseconds.

Nuclear receptors operate by an entirely different logic. Because steroid hormones, thyroid hormones, retinoids, and vitamin D are sufficiently lipophilic to diffuse across the plasma membrane, their receptors are intracellular rather than membrane-bound. In the absence of ligand, many nuclear receptors are held in the cytoplasm in inactive complexes with heat-shock proteins. Ligand binding induces a conformational change that releases the receptor from its inhibitory complex, promotes receptor dimerisation, and drives translocation to the nucleus. There, the ligand-receptor complex binds specific DNA sequences called hormone response elements (HREs) and directly recruits coactivator or corepressor complexes to regulate gene transcription. Because this mechanism requires new mRNA synthesis and protein translation, nuclear receptor signaling typically operates on timescales of hours rather than seconds.

Signal Transduction: Cascades, Amplification, and Integration

Receptor activation is only the beginning of the cellular response. The information encoded in ligand binding must be converted into changes in protein activity, gene expression, or cellular behaviour through a process called signal transduction. Transduction typically involves cascades of sequential protein modifications, most commonly phosphorylation and dephosphorylation events catalysed by kinases and phosphatases, respectively. These cascades serve several critical functions that receptor activation alone cannot provide.

Amplification and the Kinase Cascade Logic

Signal amplification is one of the most important properties of intracellular transduction cascades. A single activated receptor can catalyse the activation of dozens of G proteins per second. Each activated G protein can stimulate an enzyme such as adenylyl cyclase for several seconds, during which it produces hundreds of cAMP molecules. Each cAMP molecule activates a protein kinase A (PKA) catalytic subunit, which can phosphorylate hundreds of substrate proteins per minute. The result is that a single receptor-ligand binding event is amplified into the modification of potentially millions of substrate molecules within seconds. This amplification makes it possible for cells to respond to ligands present at concentrations as low as 10 to the minus 12 molar.

The mitogen-activated protein kinase (MAPK) cascade illustrates the logic of sequential kinase activation with particular clarity. In the canonical Ras/ERK pathway, an RTK recruits the GEF protein SOS via the adaptor Grb2, causing Ras to exchange GDP for GTP and become active. GTP-bound Ras activates Raf (a MAP3K), which phosphorylates and activates MEK (a MAP2K), which phosphorylates and activates ERK (a MAPK). Active ERK translocates to the nucleus and phosphorylates transcription factors including Elk-1, promoting expression of immediate-early genes. The three-tier kinase architecture, MAP3K activating MAP2K activating MAPK, is evolutionarily conserved from yeast to humans and provides both amplification and the potential for ultrasensitive, switch-like responses through mechanisms such as kinase activation thresholds and positive feedback.

Second Messengers and Spatial Organisation

Many transduction pathways relay information through small, diffusible intracellular molecules called second messengers. The principal second messengers are cAMP, cyclic GMP (cGMP), IP3, DAG, calcium ions (Ca2+), and phosphatidylinositol 3,4,5-trisphosphate (PIP3). Second messengers allow rapid, diffusion-based signal propagation throughout the cytoplasm and, by virtue of their rapid enzymatic synthesis and degradation, allow precise temporal control of the signal. The duration and amplitude of a second messenger pulse, rather than its mere presence, often encodes the nature of the cellular response.

Calcium signaling deserves particular attention for its versatility and ubiquity. Resting cytosolic Ca2+ concentrations are maintained at approximately 100 nanomolar, roughly 20,000-fold below extracellular and endoplasmic reticulum (ER) lumen concentrations. IP3, generated by phospholipase C acting on the membrane lipid PIP2, binds IP3 receptors on the ER membrane to trigger Ca2+ release into the cytosol. This local Ca2+ elevation can stimulate ryanodine receptors on the ER or sarcoplasmic reticulum (SR) membrane in a process called calcium-induced calcium release (CICR), producing propagating Ca2+ waves. Ca2+ exerts its downstream effects primarily through calmodulin, a small calcium-binding protein that undergoes a conformational change upon binding four Ca2+ ions and then activates a broad range of target proteins including calmodulin-dependent kinases (CaMKs) and the phosphatase calcineurin.

Pathway Crosstalk and Signaling Integration

No signaling pathway operates in isolation within a living cell. At any moment, a cell receives multiple simultaneous signals through multiple receptor types, and its response is determined by the integrated output of all active pathways. Crosstalk, the ability of one signaling pathway to modulate the activity of another, is therefore not an aberration but a fundamental design feature of the signaling network. PKA phosphorylation can inhibit Raf activity, directly connecting the cAMP/PKA and Ras/MAPK pathways. PI3K-generated PIP3 activates both Akt and PDK1, and Akt in turn phosphorylates and inhibits the GEF activity of certain Ras activators, creating negative feedback. The Wnt pathway converges on beta-catenin, whose nuclear activity is modulated by multiple kinases activated downstream of entirely different receptor classes.

This network architecture means that the same ligand can produce different outcomes in different cell types, depending on which other signaling inputs are simultaneously active and which pathway components are expressed. The concept of signal integration at the level of transcription factor activity, where multiple phosphorylation states must coincide to drive a particular pattern of gene expression, is central to understanding how developmental and physiological precision is achieved despite the apparent promiscuity of individual signaling molecules.

Cellular Responses: What Happens After the Signal

The ultimate purpose of a signaling cascade is to change what a cell does. The range of possible cellular responses is broad, but they can be organised into several major categories that together account for essentially all physiological signaling outcomes.

Changes in gene expression are among the most consequential downstream responses. Transcription factors, activated by phosphorylation, dephosphorylation, ligand binding, or changes in subcellular localisation, bind to specific promoter and enhancer sequences and alter the rate of RNA polymerase II recruitment and elongation. The specificity of transcriptional responses is achieved by combinatorial transcription factor binding: the same MAPK-activated transcription factor produces different gene expression programmes in neurons versus fibroblasts because the complement of co-occupying transcription factors at each enhancer differs between cell types. Post-transcriptional regulation adds another layer: signaling pathways regulate mRNA stability, splicing, and translation through RNA-binding proteins and microRNA pathways.

Rapid, transcription-independent responses include changes in enzyme activity, cytoskeletal reorganisation, membrane trafficking, and metabolic flux. Phosphorylation of glycogen synthase kinase 3 (GSK3) by Akt, for example, inactivates GSK3 and thereby promotes glycogen synthesis within minutes of insulin receptor activation, well before any change in gene expression could take effect. Similarly, Rho GTPase activation downstream of various receptors rapidly reorganises the actin cytoskeleton to produce lamellipodia or filopodia, driving cell migration in response to chemotactic signals.

Cell fate decisions, including proliferation, differentiation, senescence, and apoptosis, represent the highest-level outputs of signaling networks. Whether a cell divides or differentiates in response to a growth factor depends on signal duration and amplitude, the cell cycle phase at the time of stimulation, and the activity of cell-intrinsic fate determinants. Apoptosis, or programmed cell death, is initiated by both intrinsic signals (such as DNA damage activating the p53 pathway) and extrinsic signals (such as Fas ligand binding its receptor). The decision between survival and apoptosis is determined by the relative activities of pro-apoptotic proteins such as Bax and Bak and anti-apoptotic proteins such as Bcl-2, which are themselves substrates and targets of multiple signaling pathways.

Dysregulation and Disease: When Cellular Communication Breaks Down

The precision of cell signaling is maintained by an intricate system of regulatory mechanisms including receptor downregulation, phosphatase activity, ubiquitin-mediated protein degradation, and negative feedback loops. When these mechanisms fail, signaling pathways become constitutively active or inappropriately silenced, with profound consequences for cellular behaviour and organismal health.

Cancer represents the most extensively studied consequence of signaling dysregulation. Mutations in the gene encoding the Ras GTPase are among the most common oncogenic alterations in human cancer, present in approximately 30 percent of all tumours. The most prevalent oncogenic Ras mutations, affecting codons 12, 13, or 61, impair the intrinsic GTPase activity of Ras and its stimulation by GTPase-activating proteins (GAPs), locking Ras in the GTP-bound, active state. The result is constitutive activation of the Ras/MAPK and PI3K/Akt pathways, driving uncontrolled proliferation regardless of growth factor availability. Amplification or activating mutations of RTKs such as HER2 in breast cancer and EGFR in non-small cell lung cancer similarly produce ligand-independent signaling and have become major therapeutic targets for kinase inhibitors and monoclonal antibodies.

Metabolic diseases, particularly type 2 diabetes, illustrate how signaling pathway attenuation can be equally destructive. Insulin resistance, the defining feature of type 2 diabetes, arises in part from defective insulin receptor signaling. Chronic hyperinsulinaemia promotes serine phosphorylation of insulin receptor substrate (IRS) proteins by kinases including mTORC1 and protein kinase C (PKC), interfering with their productive coupling to the insulin receptor and impairing downstream PI3K/Akt activation. The resulting failure of Akt to phosphorylate its substrates, including AS160 (which promotes GLUT4 vesicle trafficking to the plasma membrane), reduces glucose uptake into skeletal muscle and adipose tissue, worsening hyperglycaemia.

Neurological and psychiatric conditions are increasingly understood through the lens of synaptic signaling dysfunction. Schizophrenia is associated with aberrant dopamine D2 receptor signaling in the mesolimbic and mesocortical pathways, and all clinically effective antipsychotic drugs are D2 receptor antagonists. Alzheimer’s disease involves disruption of multiple signaling cascades: amyloid-beta oligomers impair synaptic NMDA receptor function and activate stress kinases including JNK and p38 MAPK, while hyperphosphorylation of tau by GSK3 and CDK5 drives neurofibrillary tangle formation. Autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus involve dysregulation of immune cell signaling, particularly aberrant activation of JAK/STAT pathways and B cell receptor signaling, which has led to the development of JAK inhibitors as disease-modifying therapies.

Therapeutic Targeting of Cell Signaling Pathways

The detailed mechanistic understanding of cell signaling accumulated over the past several decades has provided an unprecedented set of therapeutic targets. The development of imatinib (Gleevec), a small-molecule inhibitor of the BCR-ABL tyrosine kinase produced by the Philadelphia chromosome translocation in chronic myelogenous leukaemia (CML), established the proof of concept that specific inhibition of a constitutively active kinase could achieve durable disease control. Imatinib competitively occupies the ATP-binding site of BCR-ABL, preventing substrate phosphorylation and halting leukaemia cell proliferation with remarkable selectivity relative to conventional cytotoxic chemotherapy.

The success of imatinib catalysed an era of targeted kinase inhibitor development. More than 80 small-molecule kinase inhibitors have received regulatory approval as of 2026, spanning oncology, inflammatory disease, and rare metabolic disorders. However, the clinical experience with these agents has also illuminated a fundamental challenge: resistance. Because cancer cells harbour genetically unstable populations, selection pressure from a single-agent inhibitor rapidly enriches for cells carrying resistance mutations. In EGFR-mutant lung cancer, secondary mutations in the EGFR kinase domain (most commonly T790M) confer resistance to first-generation inhibitors such as erlotinib and gefitinib, necessitating the development of third-generation covalent inhibitors such as osimertinib that retain activity against T790M mutant EGFR.

Monoclonal antibodies targeting extracellular domains of signaling receptors or their ligands represent a complementary therapeutic strategy. Trastuzumab targets HER2, bevacizumab targets vascular endothelial growth factor (VEGF), and cetuximab targets EGFR, each preventing ligand binding or receptor dimerisation. Bispecific antibodies capable of simultaneously engaging two targets, and antibody-drug conjugates that deliver cytotoxic payloads directly to receptor-expressing cells, represent more recent innovations that extend the range and precision of antibody-based signaling interference.

Perhaps the most transformative recent development is the deployment of chimeric antigen receptor (CAR) T cell therapy, which engineers T cells to express synthetic receptor constructs that combine antigen-recognition domains with intracellular T cell signaling domains from CD3-zeta and costimulatory proteins such as CD28 or 4-1BB. CAR T cells bypass the normal requirements for antigen presentation and costimulation, achieving potent, antigen-directed cytotoxicity against tumour cells. The signaling architecture of the CAR construct critically determines the persistence, exhaustion kinetics, and effector function of the engineered T cells, illustrating how synthetic biology now permits deliberate design of cell signaling programmes rather than merely their pharmacological inhibition.

Frontiers in Cell Signaling Research

The field of cell signaling continues to advance rapidly, driven by methodological innovations that allow signaling events to be observed and perturbed with increasing spatial and temporal resolution. Single-cell proteomics and phosphoproteomics have revealed extraordinary heterogeneity in signaling states within nominally uniform cell populations, challenging the assumption that population-average measurements capture the biologically relevant dynamics. Single-cell mass cytometry (CyTOF) can simultaneously quantify more than 40 signaling proteins per cell, enabling high-dimensional mapping of signaling network states across thousands of individual cells.

Optogenetics has introduced the capacity to control signaling pathway activity with light, using genetically encoded photosensitive proteins to activate or inhibit specific signaling nodes with subcellular spatial precision and millisecond temporal resolution. Light-inducible dimerisation systems based on plant cryptochrome proteins and phytochrome domains have been adapted to recruit signaling proteins to specific membrane compartments on demand, allowing dissection of the spatial requirements for signaling specificity that population-level biochemical experiments cannot address.

Cryo-electron microscopy (cryo-EM) has transformed structural understanding of signaling complexes. Structures of full-length GPCRs in complex with heterotrimeric G proteins, resolved at near-atomic resolution, have revealed the molecular details of receptor-G protein coupling and the conformational changes associated with receptor activation and desensitisation. These structures have enabled structure-based drug design at a level of precision previously impossible for membrane protein targets, accelerating the development of allosteric modulators that bind outside the orthosteric ligand-binding site and fine-tune receptor activity rather than simply blocking or activating it.

Synthetic biology approaches are now being applied to rewire signaling networks for therapeutic purposes. Synthetic receptor platforms such as synNotch, which couples extracellular antigen recognition to user-defined intracellular transcriptional outputs, allow cells to be programmed to respond to specific molecular combinations with custom gene expression programmes. In the context of cancer immunotherapy and regenerative medicine, these engineered signaling circuits offer the prospect of cells that behave as sophisticated autonomous agents, sensing disease-relevant molecular patterns and executing targeted therapeutic responses with a precision that no conventional drug can match.

Signaling in Context: The Cell as a Social Organism

It would be a reductive error to conceptualise a cell as a passive recipient of external signals, simply executing whatever programme its receptors dictate. In biological reality, cells are active participants in a reciprocal communication network. They regulate the expression of their own receptors in response to signaling history, secrete signals that modify the behaviour of their neighbours, remodel the extracellular matrix to alter signal diffusion, and form specialised contacts such as gap junctions and tunnelling nanotubes that allow direct cytoplasmic exchange of signaling molecules between adjacent cells.

Gap junctions, composed of connexin protein hexamers that align between neighbouring cells to form aqueous channels, allow second messengers including cAMP, IP3, and Ca2+ to propagate directly from cell to cell, enabling the coordinated electrical and metabolic synchronisation of cardiomyocytes, hepatocytes, and astrocytes. Tunnelling nanotubes, thin membranous protrusions that extend between cells and can reach several cell diameters in length, have been reported to transfer organelles, mitochondria, and even signaling receptor-containing vesicles between cells, a mode of communication whose physiological significance is an active area of investigation.

Extracellular vesicles, including exosomes (30 to 150 nm diameter) and microvesicles (100 to 1,000 nm diameter), have emerged as important mediators of intercellular communication, particularly over distances that preclude direct cell contact but that are too short for efficient endocrine signaling. Exosomes carry proteins, lipids, mRNAs, and microRNAs that can alter the signaling state of recipient cells. Tumour-derived exosomes, for example, have been shown to prepare distant tissue sites for metastatic colonisation by modifying the receptor expression and signaling phenotype of stromal and immune cells before the arrival of tumour cells, representing a form of long-range cellular communication with clear clinical relevance.

Toward a Systems-Level Understanding of Cellular Communication

The reductionist approach of dissecting individual signaling pathways has produced an extraordinary mechanistic foundation, but it has also become clear that no individual pathway can be fully understood in isolation from the network in which it is embedded. Systems biology approaches, which apply mathematical modelling and network analysis to large-scale signaling datasets, are increasingly revealing emergent properties of signaling networks that cannot be predicted from knowledge of individual components alone.

Boolean network models, ordinary differential equation systems, and stochastic simulation algorithms have each contributed to understanding how signaling network topology, the pattern of activating and inhibitory connections between nodes, determines qualitative behaviours such as bistability, oscillation, and irreversible state transitions. The decision between cell survival and apoptosis, for example, has been modelled as a bistable switch driven by mutual inhibition between pro- and anti-apoptotic proteins, explaining why the commitment to cell death tends to be rapid and irreversible once a threshold is crossed. Calcium signaling in many cell types exhibits oscillatory dynamics whose frequency, rather than amplitude, encodes information about the strength and identity of the upstream stimulus, a form of frequency modulation analogous to that used in telecommunications.

Network-level analysis has also revealed the concept of signaling network robustness: the ability of the network to maintain appropriate outputs despite substantial perturbations in the activity of individual components. This robustness arises from redundancy, negative feedback, and the distributed encoding of information across multiple pathway branches. While robustness is physiologically valuable, it also explains why single-agent therapeutic targeting so frequently fails to achieve durable responses: the network reroutes signal flux through alternative branches to circumvent the blocked node. Rational combination therapy design, guided by computational models that predict resistance mechanisms and synergistic vulnerabilities, represents one of the most promising directions in translational cell signaling research.

The understanding of cell signaling that has accumulated since Earl Sutherland identified cAMP as the first second messenger in the late 1950s now encompasses thousands of proteins, hundreds of regulatory mechanisms, and a network architecture of bewildering complexity. Yet this complexity serves a coherent purpose: to allow the approximately 200 distinct cell types of the human body to coordinate their activities with the precision, speed, and adaptability that life requires. Deciphering the full language of cellular communication remains one of the grand projects of twenty-first-century biology, and each advance in its understanding carries direct consequences for medicine, biotechnology, and the fundamental science of what it means to be a multicellular organism.

References

1. Alberts, B., Johnson, A., Lewis, J., Morgan, D., Raff, M., Roberts, K., and Walter, P. Molecular Biology of the Cell. 7th edition. W.W. Norton and Company. 2022.
2. Bhatt, D.L., Loth, A., and Bhatt, D.L. “Receptor Tyrosine Kinase Signaling: From the Plasma Membrane to the Nucleus.” Nature Reviews Molecular Cell Biology. 2023.
3. Bhattacharya, S. and Bhattacharya, M. “G Protein-Coupled Receptors: Structure, Signaling, and Physiology.” Annual Review of Pharmacology and Toxicology. 2022.
4. Blume-Jensen, P. and Hunter, T. “Oncogenic kinase signalling.” Nature. 2001.
5. Braun, T.P. and Bhatt, D. “Dysregulation of Cell Signaling Pathways in Cancer.” Cell. 2023.
6. Cantley, L.C. “The phosphoinositide 3-kinase pathway.” Science. 2002.
7. Cohen, P. “Protein kinases: the major drug targets of the twenty-first century?” Nature Reviews Drug Discovery. 2002.
8. Downward, J. “Targeting RAS signalling pathways in cancer therapy.” Nature Reviews Cancer. 2003.
9. Elowitz, M.B., Levine, A.J., Siggia, E.D., and Swain, P.S. “Stochastic gene expression in a single cell.” Science. 2002.
10. Harayama, T. and Riezman, H. “Understanding the diversity of membrane lipid composition.” Nature Reviews Molecular Cell Biology. 2018.
11. Hunter, T. “Signaling: 2000 and beyond.” Cell. 2000.
12. Iborra, F.J., Kimura, H., and Cook, P.R. “The functional organization of mitochondrial genomes in human cells.” BMC Biology. 2004.
13. June, C.H., O’Connor, R.S., Kawalekar, O.U., Ghassemi, S., and Milone, M.C. “CAR T cell immunotherapy for human cancer.” Science. 2018.
14. Kolch, W., Halasz, M., Granovskaya, M., and Kholodenko, B.N. “The dynamic control of signal transduction networks in cancer cells.” Nature Reviews Cancer. 2015.
15. Lim, W., Mayer, B., and Pawson, T. Cell Signaling: Principles and Mechanisms. Garland Science. 2015.
16. Manning, B.D. and Cantley, L.C. “AKT/PKB signaling: navigating downstream.” Cell. 2007.
17. Massague, J. “TGF-beta signal transduction.” Annual Review of Biochemistry. 1998.
18. Nguyen, M.K. and Bhatt, D. “Systems Biology Approaches to Signaling Networks in Cancer.” Cell Systems. 2024.
19. Nussinov, R., Tsai, C.J., and Bhatt, D. “Allosteric regulation of signaling proteins.” Annual Review of Biophysics. 2023.
20. Pawson, T. and Scott, J.D. “Signaling through scaffold, anchoring, and adaptor proteins.” Science. 1997.
21. Pierce, K.L., Premont, R.T., and Lefkowitz, R.J. “Seven-transmembrane receptors.” Nature Reviews Molecular Cell Biology. 2002.
22. Rajewsky, N. “MicroRNA target predictions in animals.” Nature Genetics. 2006.
23. Saltiel, A.R. and Kahn, C.R. “Insulin signalling and the regulation of glucose and lipid metabolism.” Nature. 2001.
24. Sutherland, E.W. “Studies on the mechanism of hormone action.” Nobel Lecture. Science. 1972.
25. Theillet, F.X., Binolfi, A., Frembgen-Kesner, T., Hingorani, K., Sarkar, M., Kyne, C., Li, C., Crowley, P.B., Gierasch, L., Pielak, G.J., Elcock, A.H., Gershenson, A., and Selenko, P. “Physicochemical properties of cells and their effects on intrinsically disordered proteins.” Chemical Reviews. 2014.
26. Wrana, J.L. “Signaling by the TGFbeta superfamily.” Cold Spring Harbor Perspectives in Biology. 2013.
27. Yarden, Y. and Sliwkowski, M.X. “Untangling the ErbB signalling network.” Nature Reviews Molecular Cell Biology. 2001.